Pfizer (PFE)

Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.

Company profile

Ticker

PFE

Exchange

NYSE

Website

www.pfizer.com

CEO

Albert Bourla

Incorporated

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie • Warner Chilcott ...

SEC CIK

0000078003

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Agouron Pharmaceuticals, LLC • AH Robins LLC • AHP Manufacturing B.V. • Alpharma Pharmaceuticals LLC • American Food Industries LLC • Amplyx Pharmaceuticals, Inc. • Anacor Pharmaceuticals, Inc. • Array BioPharma Inc. • Bamboo Therapeutics, Inc. • Blue Whale Re Ltd. ...

PFE stock data

1M 1Y 5Y

News

From Benzinga Pro

Pfizer Announces Top-Line Results From Phase 3 Study Of 20-Valent Pneumococcal Conjugate Vaccine In Infants; Says 20vPnC Demonstrated Favorable Safety And Tolerability Profile

12 Aug 22

Pivotal top-line data demonstrate a four-dose series of 20-valent pneumococcal conjugate vaccine candidate (20vPnC), if approved, would provide the broadest serotype coverage of any pneumococcal conjugate vaccine in

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke

11 Aug 22

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer

11 Aug 22

Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US

9 Aug 22

10 Health Care Stocks With Whale Alerts In Today's Session

9 Aug 22

Press releases

From Benzinga Pro

Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants

12 Aug 22

NextRNA Therapeutics Names Dominique Verhelle as CEO and Expands Leadership Team

11 Aug 22

NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, announces the appointment of Dominique Verhelle, PhD, MBA as the Chief Executive

Thinking about trading options or stock in Roblox, Shopify, Pfizer, Sanofi SA, or Roku?

11 Aug 22

NEW YORK, Aug. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RBLX, SHOP, PFE, SNY, and ROKU.

GLOBAL BLOOD THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GBT and Encourages Investors to Contact the Firm

9 Aug 22

GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT

8 Aug 22

Analyst ratings and price targets

Last 3 months

Average target

$51.33

Low target

$49.00

High target

$53.00

Calendar

10 Aug 22

12 Aug 22

31 Dec 22

Financial summary

Financial statements Chart PFE financial data

Quarter (USD)	Jul 22	Apr 22	Dec 21	Oct 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	1.82B	1.82B	1.82B	1.82B	1.82B	1.82B
Cash burn (monthly)	229.67M	49.5M	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	302.47M	65.19M	n/a	n/a	n/a	n/a
Cash remaining	1.52B	1.76B	n/a	n/a	n/a	n/a
Runway (months of cash)	6.6	35.5	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from Pfizer earnings reports.

Recent insider trades

PFE insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
29 Jul 22	Rady A Johnson	Phantom Stock Units SSP Common Stock	Grant	Acquire A	No	No	50.51	3	151.53	7,286
29 Jul 22	Jennifer B. Damico	Phantom Stock Units SSP Common Stock	Grant	Acquire A	No	No	50.51	25	1.26K	18,322
29 Jul 22	Albert Bourla	Phantom Stock Units SSP Common Stock	Grant	Acquire A	No	No	50.51	10	505.1	95,461
15 Jul 22	Rady A Johnson	Phantom Stock Units SSP Common Stock	Grant	Acquire A	No	No	51.75	3	155.25	7,224
15 Jul 22	Jennifer B. Damico	Phantom Stock Units SSP Common Stock	Grant	Acquire A	No	No	51.75	25	1.29K	18,150

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

PFE institutional ownership history Ownership history

66.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	3091	3173	-2.6%
Opened positions	144	563	-74.4%
Closed positions	226	135	+67.4%
Increased positions	1326	1215	+9.1%
Reduced positions	1301	1131	+15.0%

13F shares	Current	Prev Q	Change
Total value	192.47B	221.77B	-13.2%
Total shares	3.72B	3.76B	-1.1%
Total puts	51.01M	75.09M	-32.1%
Total calls	49.23M	73.29M	-32.8%
Total put/call ratio	1.0	1.0	+1.1%

Largest owners	Shares	Value	Change
Vanguard	479.07M	$24.8B	+3.0%
BLK Blackrock	408.08M	$21.13B	-0.5%
STT State Street	286.85M	$14.85B	+0.7%
Capital World Investors	219.88M	$11.38B	-7.2%
Wellington Management	216.67M	$11.22B	-2.1%
Geode Capital Management	104.9M	$5.42B	+3.8%
NTRS Northern Trust	66.51M	$3.44B	-2.2%
Charles Schwab Investment Management	59.83M	$3.1B	+13.2%
BAC Bank Of America	59M	$3.05B	+2.7%
BK Bank Of New York Mellon	54.63M	$2.83B	-0.1%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	0	-56.76M	EXIT
Capital International Investors	38.53M	+37.31M	+3059.6%
BEN Franklin Resources	26.41M	-17.78M	-40.2%
Capital World Investors	219.88M	-16.98M	-7.2%
Vanguard	479.07M	+13.79M	+3.0%
Sanders Capital	0	-12.25M	EXIT
Coatue Management	0	-10.31M	EXIT
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	2.09M	-10.16M	-83.0%
Massachusetts Financial Services	43.39M	+9.54M	+28.2%
TROW T. Rowe Price	35.34M	-7.92M	-18.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Akorn • TherapeuticsMD • GT Biopharma • Church & Dwight • Teligent • Celldex Therapeutics • Acura Pharmaceuticals • Immucell • Heron Therapeutics • Brickell Biotech

Risks

PRODUCT MANUFACTURING, SALES AND MARKETING RISKS
COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES
PRICING AND REIMBURSEMENT
U.S. HEALTHCARE REGULATION
DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS
POST-AUTHORIZATION/APPROVAL DATA
INTELLECTUAL PROPERTY PROTECTION
THIRD-PARTY INTELLECTUAL PROPERTY CLAIMS
INFORMATION TECHNOLOGY AND SECURITY
BUSINESS DEVELOPMENT ACTIVITIES
SPIN-OFF AND COMBINATION OF UPJOHN WITH MYLAN
CONSUMER HEALTHCARE JV WITH GSK
MARKET FLUCTUATIONS IN OUR EQUITY AND OTHER INVESTMENTS
COST AND EXPENSE CONTROL AND NONORDINARY EVENTS
INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS
CHANGES IN LAWS AND ACCOUNTING STANDARDS

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: admitted, bivalent, bleeding, broad, cardiomyopathy, cell, clarify, Clostridium, Codification, CureVac, DCM, decided, declaratory, dilated, disciplined, divert, Enanta, encoding, enterprise, evolve, exceed, exceeded, FASB, flexible, futility, GBT, gene, German, GmbH, Haleon, halted, heavy, HHS, Instagram, intensive, ix, Labour, lamin, LIBERTY, LMNA, London, lung, menstrual, monovalent, MSN, mutation, myeloma, NDA, nominally, peace, pharmacy, poor, pregnant, premenopausal, randomized, refractory, room, SE, sickle, similarly, simultaneously, situation, telehealth, Ukrainian, underserved, unvaccinated, urgent, vi, vii, viii, Welfare, withdrawal, women

Removed: Allogene, Aurobindo, breast, CentreOne, equal, greater, initiate, PTAB, recoverability, rolling, Teva, undertaken, USA

From filing 10-Q 2022 Q2

Financial reports

View all